



SPAFID
CONNECT

Informazione Regolamentata n. 0957-61-2021	Data/Ora Ricezione 07 Ottobre 2021 11:43:24	MTA
--	---	-----

Societa' : DiaSorin
Identificativo : 152767
Informazione
Regolamentata
Nome utilizzatore : DIASORINN01 - Ulisse Spada - Valerio
Vaccarone
Tipologia : 3.1
Data/Ora Ricezione : 07 Ottobre 2021 11:43:24
Data/Ora Inizio : 07 Ottobre 2021 11:43:26
Diffusione presunta
Oggetto : PUBLICATION OF THE SUMMARY
REPORT OF THE VOTES CAST

Testo del comunicato

See attachments.

DIASORIN: PUBLICATION OF THE SUMMARY REPORT OF THE VOTES CAST

Saluggia, October 7, 2021 – DiaSorin S.p.A. (FTSE MIB: DIA) (the “**Company**”) hereby gives notice that, pursuant to applicable laws and regulations, the summary report of the votes cast at the extraordinary meeting of shareholders of the Company, held on 4th October 2021, was made available to the public today on the Company’s corporate website (www.diasoringroup.com, section “Governance/Information for Shareholders/Shareholders meetings and board/2021”).

For further information

INVESTOR RELATIONS

Riccardo Fava

Corporate Vice President Communication & Investor Relations

Tel: +39 0161.487988

riccardo.fava@diasorin.it

Emanuela Salvini

Investor Relator

Tel: +39 0161.487567

emanuela.salvini@diasorin.it

DIASORIN

Headquartered in Italy and listed at the Italian Stock Exchange in the FTSE MIB Index, DiaSorin is a global leader in the In Vitro Diagnostic (IVD) field and is active since 2021 in the Life Science business. For over 50 years, the Company has been developing, producing and marketing reagent kits used by diagnostic laboratories worldwide. The Group operates in 5 continents through 45 companies, 4 branches, 10 manufacturing facilities and 9 research and development centres. The extensive diagnostic testing and Life Science offer, made available through continuous investments in research, positions DiaSorin as the player with the broadest range of specialty tests available within the diagnostic market, and identifies the Group as the “Diagnostic Specialist”.

More info at www.diasoringroup.com.

Fine Comunicato n.0957-61

Numero di Pagine: 3